Issue 2 2023

Acquisition International - Issue 2 2023 15 ith a unique legacy in dermatology as well as decades of cutting-edge innovation, Galderma delivers a science-based portfolio of premium flagship brands and services that spans the full spectrum of dermatology. As the pure-play dermatology category leader, the company is advancing dermatology for every skin story. “We are strategically positioned in attractive, consumer-driven segments of the dermatology market, characterised by high growth fundamentals,” explains Kristen Slaoui, who has been the Chief Corporate Development Officer at Galderma since 2020. “Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.” Kristen earned her Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College, and her PhD in Physiology from The Johns Hopkins Bloomberg School of Public Health, as well as completed an NIH Post-Doctoral Fellowship at the University of Washington in Seattle, WA. After her term in Seattle, she accepted a position in respiratory drug discovery at GSK plc, but continued her commitment to academic research by spending over a decade as an adjunct assistant professor at her alma mater, The Johns Hopkins Bloomberg School of Public Health in Baltimore, MD. Since joining Galderma, Kristen has overseen a number of significant transactions including the acquisition of Alastin Skincare in 2021, adding to Galderma’s premium portfolio. “Consumer interest in and acceptance of aesthetic procedures is increasing rapidly, and the addition of Alastin’s synergistic portfolio and expertise in science-based skincare will increase Galderma’s ability to serve the needs of both consumers and professionals,” she continues. “This acquisition will enhance Galderma’s integrated dermatology platform with a comprehensive collection of scientifically proven products for daily skincare regimens and peri-procedural use, and underscores the company’s commitment to be the partner of choice for aesthetic professionals.” Innovation is the cornerstone of Galderma’s commitment to advancing dermatology. The company stands out as one of few that are capable of inventing, developing, and bringing to market truly innovative dermatological solutions for consumer and patient needs, with bestin-class innovation capabilities benefiting from a common platform, cross-fertilisation, and balanced risk profile. W “We believe our unique, Integrated Dermatology Strategy is a key differentiator for Galderma by creating greater consumer, patient, and healthcare professional engagement, generating better customer insights and delivering continuous innovation,” Kristen elaborates, speaking of what distinguishes the company from its competitors. “We operate as a simple, coherent, and integrated dermatology company that is unique in our ability to reach the whole spectrum of consumers and healthcare professionals through a truly omnichannel, go-to-market strategy.” Healthcare professionals and customers are a key partners for Galderma, both in terms of engaging in responsible business and also increasing the reach of the firm’s products and its philosophy. Galderma is now aiming to be at the forefront of medical education and training. With approximatively a 1,500 highly specialised global salesforce, and digitalisation at the core of its strategy, Galderma offers industryleading engagement with approximatively 180,000 targeted healthcare professionals. In 2021 alone, it trained more than 100,000 healthcare professionals through its Galderma Aesthetic Injector Network. Aside from a key focus on education and innovation, Kristen is keen to point out that the dedicated team behind the scenes are just as important, calling them “a key pillar of our success”. These team members include Germain Wong, Grant Reidesel, Felix VonMoos, and Jean-Romain Falconnet, who each play their own crucial role in the company’s success. Across the company, Kristen and the firm’s management embrace diversity and respect the dignity, privacy, and personal rights of every employee. “We are committed to keeping our workplace respectful and inclusive, free of discrimination of any sort,” she states. “We expect all employees to respect the dignity and the physical and psychological integrity of our patients, consumers, colleagues, and our business partners. We are proud of our dedication to diversity and inclusion. We want to ensure that the people we do business with are aware of, share, and uphold our standards.” It was due to all of these contributing factors that enabled Galderma to recently be recognised in the M&AAwards 2022 and named Aesthetics Acquisition of the Year 2022: Galderma Skincare. Regarding the future, Kristen and the committed team now intend to continue to build the broadest portfolio of flagship brands in dermatology. “We invest in innovation and we are focused on accelerating the development and commercialising our late-stage product candidates to bring new solutions to market even faster, in line with our bold ambition to be the leading dermatology company in the world.” With the ambition to become the world’s largest independent dermatology company, Galderma has, since its inception in 1981, been a firm driven by complete dedication to dermatology. We find out more from Kristen Slaoui, a member of Galderma’s management team as the company is named within the M&A Awards 2022. Aesthetics Acquisition of the Year 2022: Galderma/ Alastin Skincare Nov22510 Contact: Kristen Sloui Company: Galderma Web Address: